Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig

  Measured over: Until all patients have completed at least 1 full Cycle (each cycle is 21 days)

• Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) population

  Measured over: From date of treatment randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)

Changes Tremor has spotted